跳到主要导航 跳到搜索 跳到主要内容

Chemoradiotherapy with extended nodal irradiation and/or erlotinib in locally advanced oesophageal squamous cell cancer: long-term update of a randomised phase 3 trial

  • Congying Xie
  • , Zhao Jing
  • , Honglei Luo
  • , Wei Jiang
  • , Li Ma
  • , Wei Hu
  • , Anping Zheng
  • , Duojie Li
  • , Lingyu Ding
  • , Hongyan Zhang
  • , Conghua Xie
  • , Xilong Lian
  • , Dexi Du
  • , Ming Chen
  • , Xiuhua Bian
  • , Bangxian Tan
  • , Bing Xia
  • , Ruifei Xie
  • , Qing Liu
  • , Lvhua Wang*
  • Shixiu Wu*
*此作品的通讯作者
  • Wenzhou Med Univ
  • Hangzhou Canc Hosp
  • 1 Peoples Hosp Huaian
  • Chinese Acad Med Sci & Peking Union Med Coll
  • Taizhou Hosp Zhejiang Prov
  • Anyang Canc Hosp
  • Bengbu Med Coll
  • Anhui Prov Hosp
  • Kaohsiung Med Univ Hosp Canc Ctr
  • Cent Hosp Lishui City
  • Zhejiang Canc Hosp
  • Jiangsu Canc Hosp
  • North Sichuan Med Coll
  • Sun Yat Sen Univ

科研成果: 期刊稿件 › 论文 › 同行评审

31 引用 (Scopus)

摘要

Background To report the long-term outcomes of a phase III trial designed to test two hypotheses: (1) elective nodal irradiation (ENI) is superior to conventional field irradiation (CFI), and (2) chemoradiotherapy plus erlotinib is superior to chemoradiotherapy in locally advanced oesophageal squamous cell cancer (ESCC). Methods Patients with locally advanced ESCC were randomly assigned (1:1:1:1 ratio) to one of the four groups: A: radiotherapy adoption of ENI with two cycles of concurrent TP chemotherapy (paclitaxel and cisplatin) plus erlotinib; B: radiotherapy adoption of ENI with two cycles of concurrent TP; C: radiotherapy adoption of CFI with two cycles of concurrent TP plus erlotinib and D: radiotherapy adoption of CFI with two cycles of concurrent TP. A total of 60 Gy of radiation doses was delivered over 30 fractions. We explored the impact of epidermal growth factor receptor (EGFR) expression on the efficacy of erlotinib plus chemoradiotherapy. Results A total of 352 patients (88 assigned to each treatment group) were enrolled. The 5-year survival rates were 44.9%, 34.8%, 33.8% and 19.6% in groups A, B, C and D, respectively (P = 0.013). ENI significantly improved OS compared with standard CFI (median, 38.5 vs 22.6 months; HR, 0.74;P = 0.018). The addition of erlotinib significantly improved OS (median, 39.4 vs 27.4 months; HR, 0.75;P = 0.025). Patients with overexpressing EGFR treated with erlotinib had a better OS and PFS than those without erlotinib. Conclusions Concurrent chemoradiotherapy with ENI and/or erlotinib improved long-term survival in locally advanced ESCC.
源语言英语
页(从-至)1616-1624
页数9
期刊British Journal of Cancer
卷123
期11
早期在线日期9月 2020
DOI
出版状态已出版 - 24 11月 2020

联合国可持续发展目标

此成果有助于实现下列可持续发展目标:

  1. 可持续发展目标 3 - 良好健康与福祉
    可持续发展目标 3 良好健康与福祉

关键词

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols
  • Chemoradiotherapy
  • Cisplatin
  • Erlotinib Hydrochloride
  • Esophageal Neoplasms
  • Esophageal Squamous Cell Carcinoma
  • Female
  • Humans
  • Lymph Nodes
  • Male
  • Middle Aged
  • Paclitaxel
  • cisplatin
  • epidermal growth factor receptor
  • erlotinib
  • paclitaxel
  • antineoplastic agent
  • adult
  • advanced cancer
  • aged
  • Article
  • biopsy
  • cachexia
  • cancer combination chemotherapy
  • cancer localization
  • cancer patient
  • cause of death
  • chemoradiotherapy
  • clinical feature
  • controlled study
  • drug efficacy
  • esophageal squamous cell carcinoma
  • esophagus perforation
  • esophagus stenosis
  • female
  • follow up
  • human
  • human tissue
  • immunohistochemistry
  • irradiation
  • major clinical study
  • male
  • open study
  • overall survival
  • phase 3 clinical trial
  • pneumonia
  • priority journal
  • protein expression
  • radiation dose
  • randomized controlled trial
  • survival rate
  • treatment failure
  • clinical trial
  • esophagus tumor
  • lymph node
  • middle aged
  • procedures
  • radiation response

收录

  • SCIE
  • Scopus

学术指纹

探究 'Chemoradiotherapy with extended nodal irradiation and/or erlotinib in locally advanced oesophageal squamous cell cancer: long-term update of a randomised phase 3 trial' 的科研主题。它们共同构成独一无二的学术指纹。

引用此